193 related articles for article (PubMed ID: 30972891)
1. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression.
Mao L; Tan J; Wang F; Luo Y; Liu W; Zeng F; Yu B; Huang H; Lu J; Peng X; Liu X
Clin Otolaryngol; 2019 Jul; 44(4):572-580. PubMed ID: 30972891
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
5. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis.
Liang ZG; Lin GX; Ye JX; Li Y; Li L; Qu S; Liang X; Zhu XD
Asian Pac J Cancer Prev; 2018 May; 19(5):1397-1404. PubMed ID: 29802706
[TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
8. Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study.
Sun XS; Liang YJ; Li XY; Liu SL; Chen QY; Tang LQ; Mai HQ
Drug Des Devel Ther; 2019; 13():3207-3216. PubMed ID: 31686783
[TBL] [Abstract][Full Text] [Related]
9. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.
Yuan JJ; Ding JW; Li JW; Hu RH; Gong D; Hu JL; Zhu KB; Liu Y; Ding YH; Wei JW; Zeng JL; Lu ZB; Yin WH; Ai SF; Zha GH; Zhang ZL; Zou R; Zeng L
BMJ Open; 2022 Aug; 12(8):e051594. PubMed ID: 36008072
[TBL] [Abstract][Full Text] [Related]
10. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
Cancer Sci; 2018 May; 109(5):1609-1616. PubMed ID: 29575438
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis.
Cai Z; Chen D; Qiu W; Liang C; Huang Y; Zhou J; Zhan Z; Xiang Y; Guo X; Lv X
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2327-2344. PubMed ID: 36289067
[TBL] [Abstract][Full Text] [Related]
12. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis.
Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
BMC Cancer; 2018 Mar; 18(1):323. PubMed ID: 29580204
[TBL] [Abstract][Full Text] [Related]
13. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
Liang R; Yang L; Zhu X
Cancer Control; 2021; 28():1073274821989301. PubMed ID: 33504193
[TBL] [Abstract][Full Text] [Related]
14. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
[TBL] [Abstract][Full Text] [Related]
15. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis.
Zhi-Qiang W; Qi M; Ji-Bin L; Rui Y; You-Ping L; Rui S; Guang-Yuan H; Ming-Yuan C; Yi-Jun H
BMC Cancer; 2019 Nov; 19(1):1122. PubMed ID: 31744469
[TBL] [Abstract][Full Text] [Related]
16. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.
Liu ZG; Zhao Y; Tang J; Zhou YJ; Yang WJ; Qiu YF; Wang H
Oncotarget; 2016 Apr; 7(17):24429-35. PubMed ID: 27016412
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
[TBL] [Abstract][Full Text] [Related]
20. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
Chen Y; Sun Y; Liang SB; Zong JF; Li WF; Chen M; Chen L; Mao YP; Tang LL; Guo Y; Lin AH; Liu MZ; Ma J
Cancer; 2013 Jun; 119(12):2230-8. PubMed ID: 23576020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
